Anti-gastric cancer drug composition and application thereof

By combining beiopronhusu with Kunming chicken blood tengxin, it induces ferrous death of gastric cancer cells, solves the drug resistance and adverse reactions in gastric cancer treatment, significantly inhibits gastric cancer cell proliferation and tumor growth, and shows good Drug safety.

CN118750487BActive Publication Date: 2024-11-19SHENZHEN LIYUNDE BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411244304.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-19
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

The treatment of gastric cancer faces the problems of increased drug resistance and adverse drug reactions. The existing technology lacks effective anti-gastric cancer drugs, especially benoproshusu and chicken blood tengxin, in terms of anti-gastric cancer.

Method used

Combining beopronhusu with Kunming chicken blood tengxin, inhibits gastric cancer cell proliferation and tumor growth by inducing ferrous death of gastric cancer cells, different concentrations of compositions were used to conduct in vitro and in vivo experiments to demonstrate that it reduces gastric cancer cell viability and inhibition Effects of tumor growth.

Benefits of technology

It significantly improved the inhibitory effect on gastric cancer cells, and the tumor suppression effect was more significant than that of medication alone. It significantly reduced the growth of gastric cancer tumors in the mouse model, and there was no abnormality in the toxicity detection of the composition on the body, showing good results. drug safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118750487B_ABST
    Figure CN118750487B_ABST
Patent Text Reader

Abstract

The present invention provides an anti-gastric cancer drug composition and its application, belonging to the field of biomedicine technology. An anti-gastric cancer drug composition comprises alloimperatorin and kunming spatholobi in a mass ratio of (25-400): (1-16). In vivo and in vitro experiments of the present invention have shown that alloimperatorin and / or kunming spatholobi increase intracellular ROS, lipid peroxides and ferrous ions, causing ferroptosis of cells, thereby achieving the effect of inhibiting the proliferation of gastric cancer cells. At the same time, in vivo experiments have also shown that alloimperatorin and / or kunming spatholobi can effectively inhibit the growth of gastric cancer tumors, and the anti-gastric cancer effect of the combined administration of the two is better than that of the single drug administration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an anti-gastric cancer drug composition and application thereof. Background Art

[0002] Gastric cancer is one of the most common malignant tumors in clinical practice. It ranks at the forefront of various malignant tumors due to its high morbidity and mortality. In recent years, with the improvement of diagnosis and treatment technology, the morbidity and mortality of gastric cancer have generally shown a downward trend. However, due to the increase of drug resistance and adverse drug reactions, the treatment of gastric cancer still faces many obstacles.

[0003] Alloimperatorin (Alloi) is a furanocoumarin compound extracted from the rhizomes of Angelica dahurica. It has anti-inflammatory and sedative effects. It can also exert anti-tumor activity by inhibiting CCL-2 chemokines and relieve various side effects after chemotherapy. Auriculasin (AC) is a polyphenolic flavonoid isolated from Fleming's bean, which generally exerts anti-inflammatory effects. There are no reports on the use of alloimperatorin and Auriculasin for the treatment of gastric cancer. Summary of the invention

[0004] In view of this, the object of the present invention is to provide an anti-gastric cancer drug composition, which combines alloimperatorin with sedum cerebroside to induce ferroptosis in gastric cancer cells, thereby inhibiting the proliferation of gastric cancer cells and the growth of gastric cancer tumors.

[0005] The present invention provides an anti-gastric cancer pharmaceutical composition, comprising alloimperatorin and kunming sedum cereus; the mass ratio of alloimperatorin to kunming sedum cereus is (25-400):(1-16).

[0006] Preferably, the mass ratio of alloimperatorin to sedumbergerain is (25-100): (1-4).

[0007] Preferably, the mass ratio of alloimperatorin to kunming millet vine is (15-25):1.

[0008] The present invention provides application of the anti-gastric cancer drug composition in preparing an anti-gastric cancer drug.

[0009] Preferably, the anti-gastric cancer effect is manifested in at least one of the following aspects: reducing gastric cancer cell viability, inhibiting gastric cancer tumor growth, and inducing ferroptosis of gastric cancer cells.

[0010] Preferably, the inducing ferroptosis of gastric cancer cells comprises increasing the content of at least one of reactive oxygen species, malondialdehyde and ferrous iron in gastric cancer cells and / or decreasing the expression level of ferroptosis-related proteins in gastric cancer cells.

[0011] Preferably, the dosage form of the drug includes at least one of the following: oral dosage form, injection dosage form and suppository.

[0012] Preferably, the concentration of imperatorin in the drug is not less than 12.5 μM;

[0013] The concentration of the kunming spatholobivine extract is not less than 0.5 μM.

[0014] The present invention provides application of the anti-gastric cancer drug composition in preparing an in vitro gastric cancer cell inhibitor.

[0015] The present invention provides a method for inhibiting the growth of gastric cancer cells under in vitro conditions, comprising the following steps: placing a gastric cancer cell sample in an environment containing alloimperatorin and / or kunming spatholobivine extract for cultivation;

[0016] The concentration of imperatorin is not less than 12.5 μM;

[0017] The concentration of the kunming spatholobivine extract is not less than 0.5 μM.

[0018] The present invention provides an anti-gastric cancer drug composition, comprising alloimperatorin and kunming spatholobi; the mass ratio of alloimperatorin to kunming spatholobi is (25-400): (1-16). In the embodiment of the present invention, the CCK8 method is used to measure the cell viability of gastric cancer cells with different concentrations of alloimperatorin and / or kunming spatholobi, and the results show that alloimperatorin or kunming spatholobi reduces the survival rate of gastric cancer cells in a dose-dependent manner, and the combined use of alloimperatorin and kunming spatholobi significantly improves the inhibitory effect on tumor cells compared with the single drug use. At the same time, a drug efficacy test was carried out on a gastric cancer model mouse as the object, and the results showed that compared with the blank control group, after treatment with alloimperatorin, kunming spatholobi and alloimperatorin and kunming spatholobi combined, the tumor growth of the gastric cancer model mouse was significantly reduced, and the inhibitory effect of the treatment group of alloimperatorin and kunming spatholobi combined was more significant than that of the single drug treatment group. In addition, by detecting the toxicity of the combined use of alloimperatorin and kunming millet vine, the results showed that the major organs of the body (heart, liver, spleen, lung, kidney) after administration were observed by naked eye without abnormal changes, and there was no significant difference compared with the blank control group, indicating that the pharmaceutical composition has good drug safety. It can be seen that the pharmaceutical composition provided by the present invention has a high-efficiency anti-cancer effect, can induce iron-induced death of gastric cancer cells, thereby regulating the death of gastric cancer cells, achieving the effect of killing tumor cells and inhibiting tumor growth. The pharmaceutical composition provided by the present invention provides a new means for the treatment of gastric cancer and the preparation of clinical drugs for gastric cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1The figure is a result graph of the cell activity of gastric cancer cells MGC-803 treated with different concentrations of alloimperatorin and / or kunming spatholobus by CCK8 method; wherein A is a result graph of the cell activity of gastric cancer cells MGC-803 treated with different concentrations of alloimperatorin, B is a result graph of the cell activity of gastric cancer cells MGC-803 treated with different concentrations of kunming spatholobus, C is a result graph of the cell activity of gastric cancer cells MGC-803 treated with 25 μM alloimperatorin and different concentrations of kunming spatholobus, and D is a result graph of the cell activity of gastric cancer cells MGC-803 treated with different concentrations of alloimperatorin and 1 μM kunming spatholobus;

[0020] Figure 2 Commercial kits were used to detect ROS, MDA and Fe in MGC-803. 2+ Horizontal result graph;

[0021] Figure 3 The results of Western blot detection of GPX4 and SLC7A11 protein expression levels in MGC-803 are shown in Figure 1; A is a Western blot detection graph, and B is a bar graph of GPX4 and SLC7A11 protein expression levels;

[0022] Figure 4 The figure shows the mean tumor volume (mean ± SD) of mice in each group. DETAILED DESCRIPTION

[0023] The present invention provides an anti-gastric cancer pharmaceutical composition, comprising alloimperatorin and kunming sedum cereus; the mass ratio of alloimperatorin to kunming sedum cereus is (25-400):(1-16).

[0024] In the present invention, the molecular formula of alloimperatorin is C 16 H 14 O4, molecular weight is 270.28, and its structural formula is shown in Formula I. The present invention does not impose any special restrictions on the source of the alloimperatorin, and the source of alloimperatorin known in the art can be used. In the present embodiment, the alloimperatorin is purchased from Wuhan Tianzhi Biological Co., Ltd.

[0025] Formula I

[0026] In the present invention, the molecular formula of the Kunming spatholobivine is C 25 H 24 O6, molecular weight is 420.45, and its structural formula is shown in general formula II. The present invention does not impose any special restrictions on the source of the Kunming spatholobus, and the source of the Kunming spatholobus known in the art can be used. In the embodiment of the present invention, the Kunming spatholobus was purchased from Wuhan Tianzhi Biological Co., Ltd.

[0027] Formula II

[0028] In the present invention, the mass ratio of alloimperatorin to kunming millet vine is preferably (25-100): (1-4), more preferably (15-25): 1, and further preferably (10-15): 1. In one embodiment of the present invention, the CCK8 method was used to detect the cell activity of gastric cancer cells (MGC-803) after treating alloimperatorin and kunming millet vine with different concentrations. The results showed that the IC 50 At around 100 μM, the IC 50 Around 4 μM. When the concentration of alloimperatorin was 25 μM and the concentration of Kunming spatholobi was 1-4 μM, or when the concentration of alloimperatorin was 25-100 μM and the concentration of Kunming spatholobi was 1 μM, the survival rate of gastric cancer cells was below 70%; and when the concentration of alloimperatorin was 25 μM and the concentration of Kunming spatholobi was 8-16 μM, or when the concentration of alloimperatorin was 200-400 μM and the concentration of Kunming spatholobi was 1 μM, the survival rate of gastric cancer cells was below 40%.

[0029] The present invention provides application of the anti-gastric cancer drug composition in preparing an anti-gastric cancer drug.

[0030] In the present invention, the anti-gastric cancer is preferably manifested in at least one of the following aspects: reducing gastric cancer cell viability, inhibiting gastric cancer tumor growth and inducing ferroptosis of gastric cancer cells. The induction of ferroptosis of gastric cancer cells preferably includes increasing the content of at least one of reactive oxygen species, malondialdehyde and ferrous iron in gastric cancer cells and / or reducing the expression of ferroptosis-related proteins in gastric cancer cells. The ferroptosis-related proteins include GPX4 and / or SLC7A11. The pharmaceutical composition inhibits the proliferation of gastric cancer cells and regulates the death of gastric cancer cells by inducing ferroptosis of gastric cancer cells, thereby achieving the efficacy of killing gastric cancer cells and inhibiting tumor growth. The ferroptosis was first proposed by Dixon et al. in 2012. This unique cell death mode is driven by iron-dependent lipid peroxidation and is regulated by a variety of cellular metabolic events, including redox homeostasis, iron metabolism, mitochondrial activity and metabolism of amino acids, lipids and sugars, as well as many signal pathways associated with diseases. The loss of membrane integrity and nuclear swelling and mitochondrial shrinkage, increased mitochondrial membrane density and rupture of the outer mitochondrial membrane are the cell morphological characteristics of ferroptosis, while the nucleus has no obvious morphological changes in ferroptosis. Ferroptosis is regulated by specific signal transduction pathways through iron accumulation, lipid peroxidation, and cell membrane damage, and can be regulated by drugs or genetic intervention. The main mechanism of ferroptosis involves regulating the homeostasis between oxidative and antioxidant systems. When two antioxidant defenses, glutathione peroxidase 4 (GPX4) and glutathione (GSH) systems, are impaired, accumulation of toxic ROS occurs, which then induces cell death. Ferroptosis, as a new way to regulate cell death, plays a vital role in killing tumor cells and inhibiting tumor growth. Therefore, using targeted induction of ferroptosis to cause gastric cancer cell death may be a new therapeutic strategy for gastric cancer.

[0031] In the present invention, the concentration of imperatorin in the drug is preferably not less than 12.5 μM, more preferably 15-60 μM, further more preferably 20-55 μM, and further more preferably 30-50 μM. The concentration of Kunming sedum cereus is preferably not less than 0.5 μM, more preferably 1-4 μM, further preferably 1.5-3 μM, and most preferably 2 μM. The dosage form of the drug preferably includes at least one of the following: oral agent, injection and suppository. The oral agent preferably includes at least one of the following: tablets, capsules, pills, sustained-release preparations and controlled-release preparations. The drug also includes pharmaceutically acceptable excipients. When the drug is prepared into tablets, it is also preferably included a carrier. The carrier preferably includes at least one of the following: diluents and absorbents, wetting agents and binders, disintegrants, disintegration inhibitors, absorption promoters, and lubricants. Common diluents and absorbents preferably include starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, white clay, microcrystalline cellulose, aluminum silicate, etc. Wetting agents and binders preferably include water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium methylcellulose, shellac, methylcellulose, potassium phosphate, polyvinyl pyrrolidone, etc. Disintegrants preferably include dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid esters, sodium lauryl sulfate, methylcellulose, ethyl cellulose, etc. Disintegration inhibitors preferably include sucrose, tristearate, cocoa butter, hydrogenated oil, etc. Absorption promoters preferably include quaternary ammonium salts, sodium lauryl sulfate, etc. Lubricants preferably include talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, etc. The tablet is preferably further made into a coated tablet, such as a sugar-coated tablet, a film-coated tablet, an enteric-coated tablet or a double-layer tablet and a multi-layer tablet. When the drug is prepared into a pill, it is preferably included in various carriers. The carrier preferably includes a diluent and absorbent, a binder, and a disintegrant. The diluent and absorbent preferably include glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc. The binder preferably includes gum arabic, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc. The disintegrant preferably includes agar powder, dry starch, alginate, sodium dodecyl sulfate, methylcellulose, ethylcellulose, etc. When the drug is prepared into a suppository, it is preferably further included in a carrier. The carrier preferably includes polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc. When the drug is prepared into capsules, the drug composition is encapsulated in the capsule shell as an active ingredient, or the active ingredient is made into microcapsules and suspended in an aqueous medium to form a suspension. The injection preferably includes at least one of the following: a solution, a suspension solution, an emulsion, and a freeze-dried powder injection.The injection can be aqueous or non-aqueous, and can contain one or more pharmacodynamically acceptable carriers, diluents, adhesives, lubricants, preservatives, surfactants or dispersants. The diluent can be selected from water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc. In addition, in order to prepare isotonic injections, an appropriate amount of sodium chloride, glucose or glycerol can be added to the injection preparation. In addition, conventional cosolvents, buffers, pH regulators, etc. can also be added. The injection is preferably administered by intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection and acupoint injection. In addition, the drug also preferably includes colorants, preservatives, spices, flavoring agents, sweeteners or other common materials for medicaments. The dosage of the drug prepared by the present invention depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight, personality and individual response of the patient or animal, the route of administration, the number of administrations, etc., so the therapeutic dose of the present invention can vary widely. According to the actual effective drug quantity contained in the final preparation of the drug of the present invention, it is appropriately adjusted to reach the requirement of its therapeutically effective amount to achieve the therapeutic purpose of the present invention.

[0032] In view of the fact that alloimperatorin and / or sedum sedum can inhibit the activity of gastric cancer cells in vitro, the present invention provides the use of the anti-gastric cancer pharmaceutical composition, alloimperatorin or sedum sedum in the preparation of in vitro gastric cancer cell inhibitors.

[0033] The present invention provides a method for inhibiting the growth of gastric cancer cells under in vitro conditions, comprising the following steps: placing a gastric cancer cell sample in an environment containing alloimperatorin and / or kunming spatholobivine for cultivation; the concentration of the imperatorin is not less than 12.5 μM; the concentration of the kunming spatholobivine is not less than 0.5 μM.

[0034] In the present invention, the environment containing alloimperatorin and / or kunming spatholobi is preferably a gastric cancer cell culture medium containing alloimperatorin and / or kunming spatholobi. The growth temperature of the gastric cancer cells is preferably 36-38°C, more preferably 37°C. The growth conditions of the gastric cancer cells are preferably 5% CO2 conditions. The concentration of the imperatorin is preferably 15-60 μM, more preferably 20-55 μM, and further preferably 30-50 μM. The concentration of the kunming spatholobi is preferably not less than 0.5 μM, more preferably 1-4 μM, further preferably 1.5-3 μM, and most preferably 2 μM.

[0035] The anti-gastric cancer pharmaceutical composition and its application provided by the present invention are described in detail below in conjunction with the examples, but they should not be construed as limiting the protection scope of the present invention.

[0036] Example 1

[0037] CCK8 was used to detect the toxicity of alloimperatorin and / or kunming sedum cerebroside on gastric cancer cells.

[0038] CCK-8 (Cat: MA0218) (meilunbio, Dalian, China) proliferation assay was used to detect the cell viability of MGC-803 cells after treatment with different concentrations of drugs (alloimperatorin or kunming millet vine or a combination of alloimperatorin and kunming millet vine). Approximately 5 × 10 3 cells / well. Then, different concentrations of alloimperatorin, kunming spatholobi and alloimperatorin + kunming spatholobi were used for 24 h. After 24 h of treatment, 10 μl / 100 μl of CCK-8 solution was added and placed at 37°C for 2 h. The test wavelength was 450 nm. The data were expressed as mean ± standard deviation, and the data were analyzed by t test.

[0039] The experimental results are as follows Figure 1 As shown in Figure 2. Cell counting kit-8 (CCK-8) assay showed that both alloimperatorin and kunming millet vine reduced the viability of MGC-803 cells in a dose-dependent manner. The IC 50 At around 100 μM, the IC 50 It is around 4 μM, and the combined use of alloimperatorin and kunming millet vine has a significantly improved inhibitory effect on tumor cells compared with the use of either drug alone.

[0040] Example 2

[0041] Detection of ROS, MDA and Fe after MGC-803 cells were treated with different concentrations of drugs 2+ level.

[0042] MGC-803 cells were treated with alloimperatorin (50 μM), kunming milletvine (2 μM), and alloimperatorin (50 μM) + kunming milletvine (2 μM) for 24 h, and ROS, MDA, and Fe in cell lysates were evaluated using H2DCF-DA (Cat: S0033) (Beyotime Biotechnology, Shanghai, China), lipid peroxidation assay kit (ab118970, Abcam), and iron assay kit (MAK025, Sigma-Aldrich), respectively. 2+ The specific procedures were carried out according to the instructions of the above-mentioned kit.

[0043] It is well known that lipid peroxidation and ferrous iron accumulation are important phenomena of ferroptosis. Figure 2The results showed that after 24 h of treatment with alloimperatorin, kunming millet vine and alloimperatorin + kunming millet vine, the intracellular ROS level increased, significantly upregulated the cellular MDA level, and triggered ferrous iron accumulation.

[0044] Example 3

[0045] The protein expression levels of GPX4 and SLC7A11 in MGC-803 were detected by Western blot.

[0046] MGC-803 cells were treated with alloimperatorin (50 μM), kunming spatholobivine (2 μM), and alloimperatorin (50 μM) + kunming spatholobivine (2 μM) for 24 h, and protein lysates were prepared using RIPA lysis buffer (Beyotime) and quantified using a BCA protein assay kit (Beyotime). Proteins were separated by SDS-PAGE and transferred to PVDF membranes. The blots were then blocked with 5% skim milk, incubated with primary antibodies overnight at 4°C, and then incubated with secondary antibodies (31430 or 31460, Invitrogen). Signals were detected using an ECL substrate (Beyotime). The primary antibodies used for western blot were as follows: anti-gpx4 (1:1000, ab125066, Abcam), anti-slc7a11 (1:1000, ab175186, Abcam).

[0047] The experimental results are as follows Figure 3 As shown. Western blotting was used to detect the effects of alloimperatorin and kunming millet vine on ferroptosis-related proteins. Compared with the control group, glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (xCT / SLC7A11) in MGC-803 cells were significantly reduced after alloimperatorin and kunming millet vine treatment. Taken together, these results indicate that ferroptosis plays a major role in gastric cancer cell death induced by alloimperatorin and kunming millet vine.

[0048] Example 4

[0049] Effects of alloimperatorin and kunming millet vine alone or in combination on gastric cancer model mice.

[0050] 1. Materials and methods.

[0051] ① Purchase of nude mice: 48 SPF-grade adult male BALB / c (nu) mice aged 6 to 8 weeks and weighing 20 ± 2 g were purchased from Kaixue Biotechnology (Shanghai) Co., Ltd. All nude mice were kept in the SPF-grade animal room of the College of Animal Science of Jilin University (temperature 18-25°C, humidity 40%-60%, and light alternation time of 12 hours). Nude mice had free access to food, which was standard laboratory-specific nude mouse feed and water. After one week of adaptive feeding, a cervical cancer model was established. In order to reduce potential experimental errors, we used nude mice of the same weight, weighing about 18 g, born in the same litter to group tumors. This experiment was a tumorigenicity experiment and was approved by the Ethics Committee of Animal Experiments of Jilin University; Approval Certificate No.: LSXK2024039.

[0052] ② Cell preparation: MGC-803 cells with good logarithmic growth phase were used for tumor transplantation experiments. After cell digestion and centrifugation, the cells were counted under a microscope.

[0053] ③ Resuspend the counted cells in sterile PBS and adjust the volume to 1 × 10 5 / mL.

[0054] ④ Use a sterile 1 mL syringe to draw 0.2 ml of the MGC-803 cell resuspension and inoculate it subcutaneously in the right axilla of BALB / c nude mice.

[0055] ⑤ Preparation of alloimperatorin and kunming millet vine solution: Alloimperatorin powder and kunming millet vine solution were dissolved in DMSO solution, diluted with sterile PBS to the required concentration, and Tween 80 was added to aid dissolution.

[0056] ⑥ After inoculation, the mice were observed every day for their status and tumor formation. The nodules under the right limbs could be felt on the 5th day. When the long diameter of the nodules was greater than 5 mm, the model was successfully constructed. When the tumor grew to the 8th day, the long and short diameters of the nodules under the right limbs of the mice were measured with a vernier caliper, and the weight of each mouse was weighed.

[0057] ⑦ The experiment was set up into 4 groups: mice with uniform tumor size were selected for grouping to reduce the error in the experiment. Nude mice were grouped, 6 mice / group. The control group was gavaged with 1% DMSO, and the positive group was given a solution of alloimperatorin, 15 mg / kg; a solution of Kunming spatholobivine, 1 mg / kg; a solution of alloimperatorin + Kunming spatholobivine, 15 mg / kg + 1 mg / kg, with gavage intervention every 3 days.

[0058] ⑧ Measure the tumor size of nude mice every 3 days with a vernier caliper, and monitor the weight, activity and diet of nude mice daily. The formula used is standard tumor volume = (1 / 2 × L × W2). Draw the growth curve of nude mouse weight and tumor volume, and calculate the tumor inhibition rate = (average tumor volume of negative control group - average tumor volume of drug group) / average tumor volume of negative control group × 100%.

[0059] ⑨ Calculate the relative tumor volume of nude mice: According to the measured tumor volume of mice, calculate the relative tumor volume according to formula I to obtain the tumor volume. Calculate the relative tumor growth rate according to formula II. A relative tumor growth rate greater than 40% is considered invalid.

[0060] The formula for relative tumor volume (RTV, Realtive tumor volume) = Vt / V0 Formula I;

[0061] Among them, Vt is the tumor volume calculated by the tumor diameter measured for mice every day, and V0 is the tumor volume calculated by the tumor diameter measured on the first day of treatment).

[0062] Tumor relative proliferation rate (T / C) = (relative tumor volume of alloimperatorin group / relative tumor volume of control group × 100%) Formula II.

[0063] ⑩After the 28th day from the beginning of the intervention, the nude mice were killed by standard cervical dislocation. After taking pictures, the tumors of the mice were removed and the size of the tumors was photographed again.

[0064] The mice were treated with 15 mg / kg alloimperatorin and 1 mg / kg Kunming sedum in combination, 15 mg / kg alloimperatorin alone, and 1 mg / kg Kunming sedum alone as the experimental group; there was also a DMSO injection group as the control group; and a paclitaxel injection group as the positive control group. There was no significant difference in the weight of the mice.

[0065] The experimental results are as follows Figure 4 As shown. The results showed that compared with the control group without medication, the tumor growth of gastric cancer model mice was significantly reduced after treatment with alloimperatorin, Kunming spatholobi and alloimperatorin + Kunming spatholobi, and the inhibitory effect of the combined drug treatment group was more significant than that of the single drug treatment group. There was no statistically significant difference in the weight of mice in the control group and the treatment group.

[0066] Example 5

[0067] Acute toxicity test of the pharmaceutical composition formed by alloimperatorin and kunming millet vine.

[0068] 1. Experimental animals.

[0069] BALB / c nude mice, weighing 20±2 g, were half male and half female. The experiment was approved by the Ethics Committee of Jilin University Animal Experiments; certificate number: LSXK2024039.

[0070] 2. Test article.

[0071] Alloimperatorin was purchased from Wuhan Tianzhi Biological Co., Ltd., with a specification of 510 mg / bottle and a purity of 98%+).

[0072] Kunming Millettia spatholobifolia was purchased from Wuhan Tianzhi Biological Co., Ltd. with a specification of 55 mg / bottle and a purity of not less than 98%.

[0073] 3. Test methods.

[0074] 40 BALB / c nude mice weighing 20±2 g, half male and half female, were randomly divided into two groups, 20 mice in each group, namely the alloimperatorin + kunming spatholobi group and the solvent control group, and the mice were fasted for 12 hours (without water restriction) before being administered. The dose of alloimperatorin in the alloimperatorin + kunming spatholobi group was 20 mg / kg, and the dose of kunming spatholobi group was 1.5 mg / kg; the solvent control group was given an equal amount of distilled water. After administration, the mice were observed for two weeks, and the behavior, activity, body weight, food intake, feces and death of the mice were recorded. The mice were killed for autopsy two weeks later.

[0075] After two weeks of administration, the mice in the Alloimperatorin + Kunming Milletvine group had smooth fur, normal behavior, weight gain, food intake, and feces, which were not significantly different from those in the solvent control group; and no death or other abnormal conditions occurred within two weeks. The two groups (Alloimperatorin + Kunming Milletvine group and solvent control group) were killed at the same time and autopsied. No abnormal changes were found in the main organs (heart, liver, spleen, lung, and kidney) by naked eye observation. There was no significant difference between the Alloimperatorin + Kunming Milletvine group and the solvent control group.

[0076] The results of the maximum tolerable dose test of the Alloimperatorin + Kunming Milletvine group after a single oral administration showed that there was no obvious toxic reaction in 20 rats after administration, and no death within two weeks. Therefore, the maximum tolerable dose of rats in the Alloimperatorin + Kunming Milletvine group after a single oral administration was greater than 20 mg / kg (Alloimperatorin) and 1.5 mg / kg (Kunming Milletvine), that is, the LD500 of the Alloimperatorin + Kunming Milletvine group after oral administration. 50 Greater than 20 mg / kg and 1.5 mg / kg.

[0077] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An anti-gastric cancer pharmaceutical composition, characterized in that: Including alloimperatorin and kunming spatholobifoliin; The mass ratio of alloimperatorin to kunming millet vine is (15-25):

1.

2. Use of the anti-gastric cancer pharmaceutical composition according to claim 1 in the preparation of anti-gastric cancer drugs.

3. The application according to claim 2, characterized in that: The anti-gastric cancer effect is manifested in at least one of the following aspects: reducing gastric cancer cell viability, inhibiting gastric cancer tumor growth, and inducing ferroptosis of gastric cancer cells.

4. The use according to claim 3, characterized in that: The inducing ferroptosis of gastric cancer cells comprises increasing the content of at least one of reactive oxygen species, malondialdehyde and ferrous iron in gastric cancer cells and / or reducing the expression level of ferroptosis-related proteins in gastric cancer cells.

5. The use according to any one of claims 2 to 4, characterized in that: The dosage form of the drug includes at least one of the following: oral dosage form, injection dosage form and suppository.

6. The use according to claim 5, characterized in that: The concentration of imperatorin in the drug is not less than 12.5 μM; The concentration of the kunming spatholobivine extract is not less than 0.5 μM.

7. Use of the anti-gastric cancer pharmaceutical composition according to claim 1 in the preparation of in vitro gastric cancer cell inhibitors.

8. A method for inhibiting the growth of gastric cancer cells in vitro, characterized in that: The following steps are involved: Gastric cancer cell samples were cultured in an environment containing alloimperatorin and kunming millet vine; The concentration of imperatorin is not less than 12.5 μM; The concentration of the kunming spatholobivine extract is not less than 0.5 μM.